Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings

Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings

Abstract Background Mycobacterium avium complex lung disease (MAC-LD) is an infection that is increasing in frequency, associated with substantial disease burden, and often refractory to treatment. Amikacin liposome inhalation suspension (ALIS) is the first therapy approved for refractory MAC-LD. In...

Full description

Bibliographic Details
Main Authors: Timothy Aksamit, Jasmanda Wu, Mariam Hassan, Emily Achter, Anjan Chatterjee
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Pulmonary Medicine
Subjects:
Liposomal amikacin
ALIS
Claims-data analysis
Healthcare resource utilization
Hospitalization
Mycobacterium avium
Online Access:https://doi.org/10.1186/s12890-022-02257-8

Similar Items

Similar Items